Dioseve, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2021

Location

Tokyo Japan

Primary Industry

Biotechnology

About

Based in Japan, and founded in 2021, Dioseve operates as a reproductive regenerative medicine company that develops infertility treatments. The company was founded by Kazuma Kishida and CTO Nobuhiko Hamasaki. In August 2022, Dioseve, Inc. raised JPY 400 million in seed funding led by ANRI and Coral Capital. Dioseve offers DIOLs (directly induced oocyte-like cells), which is a technology that produces oocyte-like cells by stimulating the development of iPS (induced pluripotent stem) cells. With the help of DIOLs technology, the company offers a wide range of infertility treatment solutions for women. The company creates primordial germ cells and adds genes to iPS cells so that infertile couples can use DIOLs to conceive children The company plans to use the funds raised in August 2022 to accelerate research, development, and recruitment.

Current Investors

ANRI, Coral Capital, Archetype Ventures

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy

Website

www.dioseve.com

Verticals

HealthTech

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.